Course of mitogen-stimulated T lymphocytes in cancer patients treated with Viscum album extracts

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2903-2910

  Bussing A ^a,d   Stumpf, C ^b   Troger W ^c   Schietzel, M ^a,b  

^a Krebsforschung Herdecke   (Germany)

^b Gemeinschaftskrankenhaus Herdecke   (Germany)

^c Krebsforschung Herdecke   (Germany)

^d UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Activation; Cancer patients; Dosage; Mistletoe; T lymphocytes; Viscum album

Indexed keywords

MITOGENIC AGENT; VISCUM ALBUM EXTRACT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DOSE ESCALATION; FEMALE; HUMAN; INJECTION SITE REACTION; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME; VISCUM ALBUM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASMS; PHYTOHEMAGGLUTININS; PLANT EXTRACTS; PLANT PROTEINS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; T-LYMPHOCYTES; VISCUM ALBUM;

EID: 34547769418     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kienle GS and Kiene H (ed.): Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen, Stuttgart, Schattauer, 2003.
2. Kienle GS, Berrino F, Bussing A, Portalupi E, Rosenzweig S and Kiene H: Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res 8: 109-119, 2003.
3. Janssen O, Scheffler A and Kabelitz D: In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittelforschung 43: 1221-1227, 1993.
4. Büssing A, Suzart K, Bergmann J, Pfuller U, Schietzel M and Schweizer K: Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins. Cancer Lett 99: 59-72, 1996.
5. + cells with a 'memory' phenotype (CD62Llo) by the N-acetyl-D-galactosamine- specific lectin from Viscum album L. Cell Death Differ 5: 231-240, 1998a.
6. Büssing A, Schaller G and Pfüller U: Generation of reactive oxygen intermediates (ROI) by the thionins from Viscum album L. Anticancer Res 18: 4291-4296, 1998b.
7. Büssing A, Vervecken W, Wagner M, Wagner B, Pfuller U and Schietzel M: Expression of mitochondrial Apo2.7 molecules and caspase-3 activation in human lymphocytes treated with the ribosome-inhibiting mistletoe lectins and the cell membrane permeabilizing viscotoxins. Cytometry 37: 133-139, 1999.
8. Bussing A (ed.): Mistletoe. The Genus Viscum. Medicinal an Aromatic Plants - Industrial Profiles. Amsterdam, Harwood Academic Publishers, 2000.
9. Berg PA and Stein GM: Beeinflusst die Misteltherapie die Abwehr epithelialer Tumoren? Eine kritische immunologische Analyse Dtsch Med Wochenschr 126: 339-345, 2001.
10. Hajto T: Immunomodulatory effects of iscador: A Viscum album preparation. Oncology 43(Suppl 1): 51-65, 1986.
11. Beuth J, Ko HL, Gabius HJ, Burrichter H, Oette K and Pulverer G: Behaviour of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients. Clinical Investigator 70: 658-661, 1992.
12. Beuth J, Ko HL, Tunggal L, Geisel J and Pulverer G: Vergleichende Untersuchungen zur immunaktiven Wirkung von Galaktosid-spezifischem Mistellektin. Reinsubstanz gegen standardisierten Extrakt. Arzneimittel- Forschung/Drug Research 43: 166-169, 1993.
13. Heiny BM and Beuth J: Misteltoe extract standardized for the galactoside-specific lectin (ML-1) induces b-endorphin release and immunopotentiation in breast cancer patients. Anticancer Research 14: 1339-1342, 1994.
14. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, Scholz M, Neiss A, Strutz J, Hennig M, Lenarz T and Arnold W: The effect of an adjuvant mistletoe treatment program in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 37: 23-31, 2001.
15. Büssing A, Rosenberger A, Stumpf C and Schietzel M: Development of lymphocyte subsets in tumor patients after subcutaneous administration of mistletoe extracts. Forsch Komplementärmed Klass Naturheilkd 6: 196-204, 1999 (in German).
16. Büssing A, Klotz M, Suzart K, Efferth T, Gerlach D, Schnitzler N, Osieka R, Schweizer K and Kaufhold A: Sister chromatid exchange-inducing DNA lesions and depression of activation markers on the surface of cultured peripheral blood mononuclear cells after the addition of streptococcal pyrogenic exotoxins A and C. Med Microbiol Immunol 184: 87-96, 1995.
17. Büssing A, Regnery A and Schweizer K: Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/ proliferation marker expression. Cancer Lett 94: 199-205, 1995.
18. Büssing A, Bischof M, Hatzmann W, Bartsch F, Soto-Vera D, Fronk EM, Gmeindl M and Stein GM: Prevention of surgery-induced suppression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients. Anticancer Res 25: 4753-4758, 2005.
19. Ostermann T, Bussing A, Beer A-M and Matthiessen PF: The Herdecke questionnaire on quality of life (HLQ): Validation of factorial structure and development of a short form within a naturopathy treated in-patient collective. Health Qual Life Outcomes 3: 40, 2005. http://www.hqlo.eom/content/3/1/ 40.
20. Mandeville R, Lamoureux G, Legault-Poisson S and Poisson R: Biological markers and breast cancer. A multiparametric study. II. Depressed immune competence. Cancer 50: 1280-1288, 1982.
21. Schink M, Troger W, Dabidian A, Goyert A, Schenerecker H, Meyer J, Fischer IU and Glaser F: Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. A randomized phase III trial. Forsch Komplementarmed 14: 9-17, 2007.